With $36bn from Teva, what should Allergan buy next?

Allergan left all options on the table in terms of the types of deals that the ever-growing company will pursue with its $36bn in after-tax proceeds from the $40.5bn sale of its generics business to Teva Pharmaceutical Industries.

Some of the money will pay down debt related to past mergers and acquisitions, but Allergan plans to spend a...